Skip to main content

Table 1 Clinical parameters of the subjects used for HBV sequencing

From: Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients

whole HBV sequencing

   
 

HCC group 1

non-HCC group 1

 
 

(n = 37)

(n = 38)

 

Age (Years)

37 ± 10.0

38 ± 11.6

 

Sex:Male

29 (78%)

28 (73%)

 

HBV-DNA (log/ml)

5.5 ± 1.1

5.2 ± 0.9

 

HBeAg positive

20 (54%)

20 (52%)

 

Platelet (× 104/μl)

11.4 ± 5.3

16.4 ± 6.0

 

Total Bilirubin (mg/dl)

1.3 ± 1.1

1.6 ± 1.97

 

Albumin (g/dl)

3.58 ± 0.8

4.0 ± 0.44

 

core promoter sequencing

   
 

HCC group 2

non-HCC group 2

pre-HCC group 2

 

(n = 40)

(n = 52)

(n = 16)

Age (Years)

54 ± 13.1

38 ± 11.4*#

48 ± 10.2

Sex:Male

78%

83%

94% *

HBV-DNA (log/ml)

5.76 ± 2.04

7.23 ± 1.37*

6.42 ± 1.66

HBeAg positive

55%

75%

79%

Platelet (× 104/μl)

12.1 ± 6.39

17.1 ± 7.15*

15.0 ± 6.59

Total Bilirubin (mg/dl)

1.32 ± 1.13

1.29 ± 2.07

2.55 ± 6.66

Albumin (g/dl)

3.58 ± 0.84

4.10 ± 0.51*

3.84 ± 0.57

  1. *p < 0.05 vs. HCC group 2, #p < 0.05 vs. pre-HCC group 2